Libertarian groups around the country are pushing state lawmakers to give drugmakers more leeway to promote their medicines with a unique message: Pharma should be protected by free speech laws.
The argument appears to be proving salient: Two states have passed laws permitting drugmakers to advertise what are known as off-label uses of drugs, and lawmakers in at least three other states are expected to take up similar bills next year. The ultimate goal, supporters told me, is to get a bill passed by Congress, a move that could reshape how the Food and Drug Administration oversees the promotion of medicine.
“The problem we see is federal law is prohibiting medical professionals from getting truthful information about lawful treatments,” Christina Sandefur, executive vice president of the Goldwater Institute, a Phoenix-based free-market/libertarian think tank, told me recently.
In seeking to loosen off-label restrictions, the Goldwater Institute and other groups are touching on the area between the FDA's authority over medicine and the practice of medicine, which is largely overseen by state medical boards. They're also trying to argue the federal government is treading on the pharmaceutical industry's right to free speech, something critics also dispute has any standing.
Off-label prescribing, when doctors give their patients medication for a use different than what the FDA approved it for, is legal and common. Some studies estimate nearly a fifth of all prescriptions are off-label. One prominent example is aspirin, which was used for years to reduce heart attacks before being approved for such a use.
Critics of this movement say many off-label uses for drugs have little rigorous scientific study to support their safety and efficacy and drugmakers already have a lot of leeway to talk to doctors about off-label uses of their products. There's also concern that the Goldwater Institute is trying to significantly lower the standard for what's considered a safe use of a drug, opening the door for the return to “snake oil” salesmen.
“Figuring out what’s truthful and not about a drug is the entire point of the FDA’s process,” Nathan Cortez, who teaches FDA law at Southern Methodist University’s Dedman School of Law, told me. “Who else is to say what’s truthful?”
The groups involved in the movement to permit off-label drug promotion are fresh off a win after President Donald Trump May 30 signed into law a bill to permit the terminally ill to sidestep the FDA in getting access to experimental drugs, a policy known as right to try. They're hoping to repeat that success and turn another relatively unknown issue into federal law within a few years.
Read my story here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)